# Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure

> **NCT05211167** · PHASE3 · UNKNOWN · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 300 (estimated)

## Conditions studied

- Kidney Failure, Chronic
- Hemodialysis

## Interventions

- **DRUG:** Human Erythropoiesis Injection (CHO cell)
- **DRUG:** Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)

## Key facts

- **NCT ID:** NCT05211167
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05211167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05211167, "Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05211167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*